LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)

Market Cap	4.45B +11.9%
Revenue (ttm)	915.53M -6.6%
Net Income	49.21M -18.1%
EPS	0.10 -18.0%
Shares Out	510.66M
PE Ratio	90.46
Forward PE	n/a
Dividend	0.01 (0.13%)
Ex-Dividend Date	Jun 24, 2025

Volume	11,092,600
Average Volume	10,470,222
Open	8.71
Previous Close	8.92
Day's Range	8.67 - 8.96
52-Week Range	6.72 - 11.85
Beta	0.41
RSI	48.48
Earnings Date	Apr 9, 2026

About SHE:002644

LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing and selling of Chinese herbal medicine pieces; and production and sales of medical devices, such as protective masks. In addition, the company exports ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 1,362
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002644

Financial Performance

In 2025, SHE:002644's revenue was 915.53 million, a decrease of -6.60% compared to the previous year's 980.23 million. Earnings were 49.21 million, a decrease of -18.08%.